Back to top
more

Zoetis (ZTS)

(Delayed Data from NYSE)

$170.37 USD

170.37
5,361,644

-4.90 (-2.80%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $170.37 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 251)

Industry: Medical - Drugs

Zacks News

Zoetis (ZTS) Beats on Q1 Earnings & Sales, Retains '18 View

Zoetis (ZTS) exceeds both earnings and sales expectations in the first quarter of 2018.

    Zoetis (ZTS) Q1 Earnings & Revenues Surpass Estimates

    Zoetis surpassed earnings and sales estimates in the first quarter of 2018.

      Zoetis (ZTS) Up 7.8% Since Earnings Report: Can It Continue?

      Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

        Madeleine Johnson headshot

        Bear of the Day: Endo International (ENDP)

        Litigation has hit this opioid drug maker hard. Is there any chance for a rebound?

          M&A, Innovation & New Drugs to Drive Pharma Stocks

          The new tax law, which cuts the corporate tax rate from 35% to 21% and encourages companies to bring back cash held overseas at a one-time tax rate of 10%, is expected to spur merger activity.

            The Zacks Analyst Blog Highlights: Texas Instruments, Statoil, Comcast, Zoetis and HP

            The Zacks Analyst Blog Highlights: Texas Instruments, Statoil, Comcast, Zoetis and HP

              Mark Vickery headshot

              Top Stock Reports for Texas Instruments, Statoil & Comcast

              Today's Research Daily features new research reports on 16 major stocks, including Texas Instruments (TXN), Statoil (STO) and Comcast (CMCSA).

                Zoetis (ZTS) Q4 Earnings & Revenues Surpass Estimates

                Zoetis surpassed earnings and sales estimates in the fourth quarter of 2017.

                  Teva Completes Sale of Women's Health Segment for $703M

                  Teva Pharmaceutical (TEVA) sells woman health specialty products for cash consideration of $703 million.

                    David Bartosiak headshot

                    5 Stocks You Can't Afford to Ignore

                    These five stocks are breaking out to new highs as earnings estimates continue to come in to the upside.

                      Zacks.com featured highlights include: Tempur Sealy, MSCI, Zoetis, Darden Restaurants and Illinois Tool Works

                      Zacks.com featured highlights include: Tempur Sealy, MSCI, Zoetis, Darden Restaurants and Illinois Tool Works

                        Mark Vickery headshot

                        Top Stock Reports for Apple, Facebook & MetLife

                        Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Facebook (FB) and MetLife (MET).

                          Zoetis (ZTS) Q3 Earnings & Sales Beat Estimate; 2017 View Up

                          Zoetis (ZTS) announced third quarter results with earnings and sales both beating estimates.

                            Mark Vickery headshot

                            Top Stock Reports for Cisco, Enterprise Products Partners & Prudential

                            Today's Research Daily features new research reports on 16 major stocks, including Cisco (CSCO), Enterprise Products Partners (EPD), and Prudential (PRU).

                              Zoetis (ZTS) Beats on Q2 Earnings & Sales, Ups 2017 View

                              Zoetis (ZTS) reported impressive second-quarter results beating on both counts. The new launches and expansion of market for major products helped revenue growth.

                                Zoetis (ZTS) Q2 Earnings In-line, Sales Beat; 2017 View Up

                                Zoetis (ZTS) reported an in-line earnings per share while revenues beat estimates in the second quarter 2017.

                                  Should You Buy Zoetis (ZTS) Ahead of Earnings?

                                  Zoetis (ZTS) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.

                                    Is Zoetis (ZTS) Poised for a Beat This Earnings Season?

                                    Zoetis, Inc. (ZTS) is expected to focus on performance of companion animal business during its second-quarter results.

                                      Adamas Provides Positive Long-term Data on Parkinson's Drug

                                      Adamas Pharmaceuticals, Inc. (ADMS) presented expanded analysis from an ongoing open label phase III study EASE LID 2 on its lead candidate, ADS-5102 extended-release capsules.

                                        Zoetis (ZTS) Up 6.4% Since Earnings Report: Can It Continue?

                                        Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                          Roche (RHHBY) Presents Positive Data on IPF Drug Esbriet

                                          Roche Holding AG (RHHBY) announced new retrospective data analyses for idiopathic pulmonary fibrosis (IPF) drug, Esbriet.

                                            Inovio (INO) Stock Rises on Encouraging HIV Vaccine Data

                                            Inovio Pharmaceuticals Inc. (INO) shares have rallied 12% since the company announced that its HIV vaccine evoked almost 100% immune response rates in a clinical study

                                              Horizon (HZNP) Sells European Rights for Procysbi & Quinsair

                                              Horizon Pharma plc (HZNP) signed an agreement with Chiesi Farmaceutici S.p.A. to sell European rights for Procysbi and Quinsair.

                                                Roche's Arthritis Drug Gets FDA Nod for Label Expansion

                                                Roche Holdings AG (RHHBY) announced that the FDA has approved Actemra subcutaneous injection for the treatment of giant cell arteritis (GCA).

                                                  Celgene (CELG) Multiple Sclerosis Drug Meets Primary Endpoint

                                                  Celgene Corporation (CELG) announced positive results from the phase III trial, RADIANCE that evaluated the efficacy and safety of experimental candidate ozanimod.